Optimizing Switch Strategies for Patients With Viral Suppression

In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.

Presenters:

Daniel R. Kuritzkes, MD
Chief, Division of Infectious  
Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Chloe Orkin, MBChB, FRCP, MD
Professor of HIV  
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Link to full program:
https://bit.ly/2TXTYWx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.